Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peripheral acute leukemia: high peripheral but low-marrow blast count.

J D Cason1, J M Trujillo, E H Estey

  • 1Department of Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston.

Blood
|October 1, 1989
PubMed
Summary

Patients with over 30% peripheral blasts, even with less than 30% marrow blasts, may have acute leukemia. This finding suggests a reclassification for these myelodysplastic syndrome cases to improve early diagnosis and treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Leukemia·2017
Same author

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Leukemia·2017
Same author

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Leukemia·2016
Same author

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

Leukemia·2016
Same author

Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Leukemia·2016
Same author

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Leukemia·2015

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
  • Current diagnostic criteria for acute myeloid leukemia (AML) rely heavily on marrow blast percentage.

Observation:

  • Five patients presented with >30% peripheral blasts and <30% marrow blasts.
  • These cases would typically be classified as MDS under existing standards.
  • Four patients progressed to AML within 1.5 months; one progressed 2 years later.

Findings:

  • Peripheral blast percentage may be a critical indicator for AML diagnosis.
  • Two patients showed AML evidence beyond marrow blasts: dermal involvement and t(8;21) cytogenetic abnormality.
  • The study suggests reclassifying patients with >30% peripheral blasts as AML, irrespective of marrow blast count.

Related Experiment Videos

Implications:

  • This challenges current AML diagnostic thresholds, potentially leading to earlier intervention.
  • Consideration of peripheral blast count alongside marrow blasts could refine AML classification.
  • Earlier AML diagnosis may improve patient outcomes and treatment strategies.